SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of_______, 2020, between GT Biopharma, Inc., a Delaware corporation and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
CONVERTIBLE NOTE DUE ______________Convertible Security Agreement • May 15th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of GT BIOPHARMA, INC., a Delaware corporation, (the “Borrower”), having its principal place of business at 9350 Wilshire Blvd, Suite 203, Beverly Hills, CA 90212, due ______________ (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 15th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of ____2020, by and among GT Biopharma, Inc., a Delaware corporation, with headquarters located at 9350 Wilshire Blvd, Suite 203, Beverly Hills, CA 90212 (the "Company"), and the investors listed on the Schedule of Purchasers attached hereto (each, a "Purchaser" and collectively, the "Purchasers").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of ______________, between GT Biopharma, Inc., a Delaware corporation and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
Clinical Trial AgreementClinical Trial Agreement • May 15th, 2020 • GT Biopharma, Inc. • Pharmaceutical preparations
This Clinical Trial Agreement (“Agreement”) is made as of this ___ day of September 2019 (the “Effective Date”) by and between Regents of the University of Minnesota, a non-profit, educational, and research (“Institution”) with an address at Sponsored Projects Administration, 450 McNamara Alumni Center, 200 Oak Street S.E., Minneapolis, MN 55455 and GT Biopharma, Inc., a Delaware corporation having its principal place of business 9350 Wilshire Blvd., Suite 203, Beverly Hills, CA 90212 (“Sponsor”). Sponsor and Institution are herein referred to collectively as “Parties.” Individually, each of Sponsor and Institution is a “Party”.
